Page 237 - Drug Class Review

Drug Effectiveness Review Project
Groups similar at baseline: No; significantly more females randomized to DON
Alzheimer classification: Mild-moderate-severe

Health Outcome Measures: DON

galantamine donepezil 72.8 74.1 68.2 56.4 98.9 100 14.8 15.1 Primary Outcome Measures: BADLS Secondary Outcome Measures: MMSE; ADAS-Cog 11; NPI; SCGB Timing of assessments: Baseline and weeks 13, 26 and 52 BADLS scores showed no significant difference between treatment groups in mean change from baseline to week 52 Changes from baseline in NPI similar for both treatments At endpoint, a higher percentage of GAL than DON patients reported maintenance or improvement of objective and subjective caregiver burden (SCGB); 67.1% and 68.3% respectively

• • • • •

Final Report Update 1 Authors: Wilcock et al. Year: 2003 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% white): Other germane population qualities: Mean screening MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs